Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1406-1418

  Rodríguez García, Alba ^a   Giménez Alejandre, Marta ^b   Rojas, Juan J ^c   Moreno, Rafael ^a   Bazan Peregrino, Miriam ^b   Cascalló, Manel ^b   Ramon, Alemany ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b VCN Biosciences   (Spain)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ARGINYLGLYCYLASPARTIC ACID; ASPARTATE AMINOTRANSFERASE; CREATININE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPARAN SULFATE; HYALURONIDASE; INTERLEUKIN 6; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS ICOVIR 17; ONCOLYTIC ADENOVIRUS VCN 01; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; CARRIER PROTEIN; HYALURONOGLUCOSAMINIDASE; ONCOLYTIC VIRUS; PROTEIN BINDING; PROTEOHEPARAN SULFATE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ADMINISTRATION ROUTE; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TUMOR LEVEL; FIBROBLAST; HAMSTER MODEL; HUMAN; HUMAN CELL; IC50; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LIGAND BINDING; LIVER HEMORRHAGE; LIVER NECROSIS; MALE; MELANOMA; MONOCYTOSIS; MOUSE; MOUSE MODEL; NEUTROPHILIA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTHROMBIN TIME; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TOXICITY TESTING; TUMOR MODEL; UPREGULATION; VIREMIA; VIRUS PARTICLE; VIRUS REPLICATION; ADENOCARCINOMA; ADENOVIRIDAE; ADVERSE EFFECTS; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; BIOSYNTHESIS; CELL LINE; DRUG SCREENING; EXTRACELLULAR MATRIX; FEMALE; GENETICS; HAMSTER; HEK293 CELL LINE; MESOCRICETUS; METABOLISM; PANCREATIC NEOPLASMS; PROCEDURES; TUMOR CELL LINE; VIROLOGY;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; BINDING SITES; CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; CRICETINAE; EXTRACELLULAR MATRIX; FEMALE; HEK293 CELLS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; HYALURONOGLUCOSAMINIDASE; ISLETS OF LANGERHANS; MALE; MELANOMA; MESOCRICETUS; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927645890     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2213     Document Type: Article

References (50)

1. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 2013;12:103.
2. Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev Vaccines 2013;12: 1155-72.
3. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658-70.
4. Alemany R. Chapter four-Design of improved oncolytic adenoviruses. Adv Cancer Res 2012;115:93-114.
5. Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA, et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2010;2:2290-355.
6. Nicol CG, Graham D, Miller WH, White SJ, Smith TA, Nicklin SA, et al. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 2004;10:344-54.
7. Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M, et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003;14:1595-604.
8. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K, et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003;14:777-87.
9. Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, Alemany R. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 2006;87:2487-95.
10. Kritz AB, Nicol CG, Dishart KL, Nelson R, Holbeck S, Von Seggern DJ, et al. Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Mol Ther 2007;15:741-9.
11. Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, Hemminki A, et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther 2009;20:1214-21.
12. Rojas JJ, Gimenez-Alejandre M, Gil-Hoyos R, Cascallo M, Alemany R. Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Gene Ther 2011;19:453-7.
13. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev 2005;5:965-76.
14. Smith E, Breznik J, Lichty BD. Strategies to enhance viral penetration of solid tumors. Hum Gene Ther 2011;22:1053-60.
15. Strauss R, Lieber A. Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo. Curr Opin Mol Ther 2009;11:513-22.
16. Choi IK, Lee YS, Yoo JY, Yoon AR, Kim H, Kim DS, et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther 2010;17:190-201.
17. Dmitrieva N, Yu L, Viapiano M, Cripe TP, Chiocca EA, Glorioso JC, et al. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res 2011;17:1362-72.
18. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007;67:4399-407.
19. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006;98:1482-93.
20. Schafer S, Weibel S, Donat U, Zhang Q, Aguilar RJ, Chen NG, et al. Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors. BMC Cancer 2012;12:366.
21. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010;18:1275-83.
22. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62:112-20.
23. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-29.
24. Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010;9:3052-64.
25. Batra SK, Metzgar RS, Worlock AJ, Hollingsworth MA. Expression of the human MUC1 mucin cDNA in a hamster pancreatic tumor cell line HP-1. Int J Pancreatol 1992;12:271-83.
26. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-78.
27. Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, et al. A modi fied E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene therapy 2009;16:1441-51.
28. Dorfman A, Ott ML. Aturbidimetric method for the assay of hyaluronidase. J Biol Chem 1948;172:367-75.
29. Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007;15: 1607-15.
30. Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R, et al. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther 2012;19:1048-57.
31. Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F, et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 2010;18:1960-71.
32. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006;66:1270-6.
33. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-6.
34. Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K, Wildner O. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol 2006;80:3549-58.
35. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15:1157-66.
36. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001;8:746-59.
37. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001;3:697-707.
38. Gregory SM, Nazir SA, Metcalf JP. Implications of the innate immune response to adenovirus and adenoviral vectors. Future Virol 2011;6:357-74.
39. He D, Sun L, Li C, Hu N, Sheng Y, Chen Z, et al. Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of Newcastle disease virus in vitro and in vivo. Viruses 2014;6:856-74.
40. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV, et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther 2009;16:644-54.
41. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006;14:107-17.
42. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, et al. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 2009;16:625-37.
43. Bernt KM, Ni S, Gaggar A, Li ZY, Shayakhmetov DM, Lieber A. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 2003;8: 746-55.
44. Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, Broadt T, et al. Identifying the safety pro file of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol 2007;196:389 e1-9; discussion e9-10.
45. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004;78:5368-81.
46. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WSM. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the syrian hamster model. Mol Ther 2008;16: 1665-73.
47. Kultti A, Li X, Jiang P, Thompson CB, Frost GI, Shepard HM. Therapeutic targeting of hyaluronan in the tumor stroma. Cancers 2012;4: 873-903.
48. Baumgartner G, Gomar-Hoss C, Sakr L, Ulsperger E, Wogritsch C. The impact of extracellular matrix on the chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 1998;131:85-99.
49. Puig-Saus C, Gros A, Alemany R, Cascallo M. Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers. Mol Ther 2012;20:54-62.
50. Puig-Saus C, Laborda E, Rodriguez-Garcia A, Cascallo M, Moreno R, Alemany R. The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model. Cancer Gene Ther 2014;21:68-73.